Long-term adherence to antiretroviral therapy in resource-limited settings: A bitter pill to swallow

Antiviral Therapy

Volumn 18, Issue 1, 2013, Pages 25-28

  Bangsberg, David R ^a,b,c,d   Mills, Edward J ^e,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^e UNIVERSITY OF OTTAWA   (Canada)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; CD4+ T LYMPHOCYTE; HEALTH CARE ACCESS; HEALTH ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SOCIAL STATUS; SOCIAL SUPPORT; TREATMENT FAILURE;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84874410220     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2536     Document Type: Review

References (28)

1. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
2. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
4. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010; 55:460-465.
5. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
6. Meresse M, Carrieri MP, Laurent C, et al. Time patterns of adherence and long-term virological response to nonnucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther 2013; doi: 10.3851/IMP2535.
7. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA 2006; 296:679-690.
8. Adakun SA, Siedner MJ, Muzoora C, et al. Higher baseline CD4 count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr 2012; in press.
9. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: A systematic review. AIDS 2012; 26:2059-2067.
10. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3:e438.
11. Ahonkhai AA, Noubary F, Munro A, et al. Not all are lost: Interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS ONE 2012; 7:e32993.
12. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: A systematic review. Trop Med Int Health 2011; 16:1297-1313.
13. Ware NC, Wayatt MA, Geng E, et al. Missed clinic visits and disengagement from HIV treatment and care in sub-Saharan Africa: A qualitative study. PLoS Med 2012; in press.
14. Nakimuli-Mpungu E, Bass JK, Alexandre P, et al. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: A systematic review. AIDS Behav 2012; 16:2101-2118.
15. Ford N, Darder M, Spelman T, Maclean E, Mills E, Boulle A. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: Five-year follow up of an observational cohort. PLoS ONE 2010; 5:e10460.
16. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE 2009; 4:e7196.
17. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: A systematic review of evaluation studies. Lancet Infect Dis 2011; 11:942-951.
18. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011; 8:e1000422.
19. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: A randomized controlled trial of text message reminders. AIDS 2011; 25:825-834.
20. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): A randomised trial. Lancet 2010; 376:1838-1845.
21. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: A systematic review and meta-analysis of randomised clinical trials. Lancet 2009; 374:2064-2071.
22. Nachega JB, Chaisson RE, Goliath R, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010; 24:1273-1280.
23. Chang LW, Kagaayi J, Nakigozi G, et al. Effect of peer health workers on AIDS care in Rakai, Uganda: A clusterrandomized trial. PLoS ONE 2010; 5:e10923.
24. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique. J Acquir Immune Defic Syndr 2011; 56:e39-344.
25. Lachetti C, Ioannidis JP, Guyatt G. Surprising Results of Randomized Trials. In Guyatt G, Rennie D, Meade MO, Cook DJ (Editors). Users' Guides to the Medical Literature. Chicago: AMA Press 2008; pp. 113-149.
26. Lambdin BH, Micek MA, Koepsell TD, et al. Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique. J Acquir Immune Defic Syndr 2011; 57:e33-e39.
27. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008; 5:e109.
28. Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav 2010; 14:1340-1346.